Close

Needham & Company Reiterates Buy Rating, $8 Price Target on CTI BioPharma (CTIC) Following Q1 Report, "We Are Encouraged by Initial Strong Numbers"

May 13, 2022 6:22 AM EDT Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $8.00 price target on CTI BioPharma (NASDAQ: CTIC), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login